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journal homepage: www.jfma-onl ine.comLETTER TO THE EDITORRisk of endotoxemia associated with clinical
incidence of contaminated propofolDear Editor,
I read the interesting short communication of Shy-Hong and
colleagues, in which they confirmed, in a different way
than usual, the infectious risks for endotoxemia associated
with propofol contamination. They did this through the
report of four consecutive patients.1 I would like to add
further clinical information and epidemiological outcomes,
which the authors did not consider, but which I consider are
important to aid the discussion about this topic that prob-
ably represents a public health problem in many countries.
Although there are multiple preservative substances
that are added to propofol with the objective of reducing
infectious risks and reducing probiotic characteristics, it is
important to have careful management and to use the
manipulation guidance given by most manufacturers. Since
the introduction of propofol by the US Food and Drug
Administration in 1989, it has been implicated in several
outbreaks of postoperative sepsis, even including many
fatalities. Furthermore, many studies have confirmed the
involvement of propofol contamination in bacterial growth
and its support of endotoxin production. There is clinical
evidence of fungal infections originating after propofol in-
fusions (relative risk Z 8.8, p Z 0.048), and also by bad
conditions during its administration.2 In 1999, Henry et al
conducted a caseecontrol study, in which they concluded
that the infusion of propofol is an important risk factor for
infections (odds ratio Z 22, 95% confidence
interval Z 2.1e550).3 Other studies have mentioned the
incidence of ampules with contaminated propofol. Webb
et al retrospectively obtained a value of 5.6% (18/302)
infected ampules in the intensive care unit.4 However, the
results exposed by Shy-Hong and colleagues have already
been mentioned in other in vitro studies. Arduino and
colleagues measured endotoxin concentration of four
Gram-negative bacteria (isolated from outbreak cases and
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http://dx.doi.org/10.1016/j.jfma.2014.01.012Limulus amebocyte gel-clot assay method. They concluded
that there was strong endotoxin production postinoculation
in propofol, increasing the concentration from 0 ng/mL to
14.72 ng/mL after 72 hours in the most extreme case of
Enterobacter cloacae.5
Finally, I would like to congratulate the effort of the
authors on this line of investigation and I would also like to
encourage the development of new studies in vivo to
analyze the association of propofol in postoperative
infections.
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